Breast Cancer Molecular Subtypes and Associations with Clinicopathological Characteristics in Iranian Women, 2002-2011

Disease Free Survival among Molecular Subtypes of Early Stage Breast Cancer between 2001 and 2010 in Iran

“…Lymph node involvement was 57.7%, distant metastasis was 15.5% which the results were similar to study of Bennis et al (2012) 53% and 17.5% respectively, but a higher lymph node involvement comparing to other studies 41% and 39% respectively (Millar et al, 2009;Voduc et al, 2009), could be due to a delay of diagnosis comparing to western studies because of a lack of knowledge in our patients or a defect of screening or lack of appropriate medical services.The most common pathologic types in our study were invasive ductal carcinoma similar to other studies in the world (Chen et al, 2012;Kadivar et al, 2012). Estrogen hormonal receptor existed in 66.6% of patients similar to different papers (Allred et al, 1998;Kadivar et al, 2012).HER-2 overexpression incidence rate in our study was 16.4%, minimally lower than the reported rate in other studies (Ross et al, 2004), subsequently the difference may be due to a difference in laboratory methodes.In our study prevalence of luminal A was 61%, triple negative 22.6%, luminal B 8.3%, and HER-2 enriched was 8.1% similar to Iranian and Chinese study (Chen et al, 2010;Kadivar et al, 2012). As the same as other studies most of tumors under 2 cm were in luminal A group (Voduc et al, 2009;Kadivar et al, 2012).…”

“…Estrogen hormonal receptor existed in 66.6% of patients similar to different papers (Allred et al, 1998;Kadivar et al, 2012).HER-2 overexpression incidence rate in our study was 16.4%, minimally lower than the reported rate in other studies (Ross et al, 2004), subsequently the difference may be due to a difference in laboratory methodes.In our study prevalence of luminal A was 61%, triple negative 22.6%, luminal B 8.3%, and HER-2 enriched was 8.1% similar to Iranian and Chinese study (Chen et al, 2010;Kadivar et al, 2012). As the same as other studies most of tumors under 2 cm were in luminal A group (Voduc et al, 2009;Kadivar et al, 2012). In our study most of tumors over 5 cm were in triple negative group while in the mentioned study, the most common cases were in HER-2 enriched (7%);(16.3) and then triple negative (6%);(10.7) groups respectively (Voduc et al, 2009;Kadivar et al, 2012), that the difference is little.…”

“…As the same as other studies most of tumors under 2 cm were in luminal A group (Voduc et al, 2009;Kadivar et al, 2012). In our study most of tumors over 5 cm were in triple negative group while in the mentioned study, the most common cases were in HER-2 enriched (7%);(16.3) and then triple negative (6%);(10.7) groups respectively (Voduc et al, 2009;Kadivar et al, 2012), that the difference is little. The most tumors with grade 3 and the least tumors with grade 1 were triple negative,similar to Korean study (Noh et al, 2011) and this could be due to the nature of these tumors.The triple negative group had fewer lymph node positive cases comparing to other groups (Voduc et al, 2009), and this could be due to more blood spreading in these tumors.The luminal A group had a lowest metastasis rate (7.8%) and the HER-2 enriched group had the highest metastasis rate (25%) while in study of Bennis et al (2012) the highest distant metastasis rate was in group luminal B (24%) and the lowest was in group, HER-2 enriched (13%) (Bennis et al, 2012), which according to the survival in the studied groups,the results have been reasonable and logical.…”

“…The knowledge about periods of risks and common site of disease relapse could be used as a guide for focusing on clinical history and physical exams during the follow up visits and screening tests which provide the most information. Mean age of diagnosis in our study was 47.9±9.6 which was lower comparing to study of Su et al (2010) and Kadivar et al (2012) with a mean age of 53±10.4 years old at the time of diagnosis but Bennis et al (2012) similar to Tunisian study in which the mean age of diagnosis was reported 46.8±12 and Haghighat et al (2012) was higher comparing to Iranian study with a mean age of 45.9±10.5. In our patients 9% were under 35 years old and 63.5% were over 50 years old,similar to other Iranian study, patients under 35 years old were 12% and patients over 50 years old were 42% (Kadivar et al, 2012), with regard to study of Webster et al (2008) patients under 35 years old were 6.2% and patients over 50 years old were 37.8% (Webster et al, 2008), our patients had breast cancer at a younger age,possibily due to ethnic and genetic differences.…”

Clinicopathological Features of Indonesian Breast Cancers with Different Molecular Subtypes

“…Studies in Iran got lower results in which the mean age at diagnosis was 50±12 years old and 47.9 years old (Kadivar et al, 2012;Najafi et al, 2013), meanwhile higher mean of patient's age (62.7%) was found in Marshfiled Clinic/St Joseph Hospital Wisconsin study (Onitilo et al, 2009). In this study the number of breast cancer patients of >50 years old was higher (54.8%) compared to <50 years old patients (45.2%).…”